Considerations for best practices related to sodium-glucose cotransporter-2 inhibitors and serum potassium levels

Am J Health Syst Pharm. 2021 Jul 22;78(15):1367-1368. doi: 10.1093/ajhp/zxab122.

Authors

Elizabeth Van Dril¹, Christine Schumacher^{2

3}

Affiliations

¹ Department of Pharmacy Practice University of Illinois at Chicago College of Pharmacy University of Illinois Hospital and Health Sciences System Chicago, IL, USA.
² Department of Pharmacy Practice Midwestern University College of Pharmacy Downers Grove, IL, USA.
³ Advocate Medical Group Chicago, IL, USA.

PMID: 33764438
DOI: 10.1093/ajhp/zxab122

No abstract available

Keywords: SGLT2 inhibitor; serum potassium.

Publication types

Letter
Comment

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy
Humans
Hypoglycemic Agents
Potassium* / blood
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Hypoglycemic Agents
Potassium
Sodium-Glucose Transporter 2 Inhibitors